Download - UCB Inspired by patients. Driven by science. · Disclaimer and safe harbor 2018 3M report 2 Forward-looking statements This presentation contains forward-looking statements, including,

UCB Inspired by patients.Driven by science.

3 months interim Report

Brussels, 25 April 2018

2018 3M reportDisclaimer and safe harbor 2

Forward-looking statementsThis presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”,“expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward-looking statements are basedon current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performanceand are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance orachievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied bysuch forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitiveconditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research anddevelopment, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmentalinvestigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchangerate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is noguarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developedand approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject todifferences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they aremarketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and thereimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-lookingstatements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statementsin this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which anysuch statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

2018 3M reportUCB is progressing on our strategic growth path 3

1 CRL: complete response letter2 NME: New Molecular Entity

Grow core productsCimzia®, Vimpat®, Keppra®, Briviact® + Neupro®

combined net sales: € 839 billion (-2%; +8% CER)

Advance and prepare launch of next wavepadsevonil Phase 2b start

Deliver breakthrough solutionsClinical development pipeline with 13 NMEs²UCB0107 (anti-Tau antibody) first in man

Continued focusCreation of SyndesiAcquisition of Element GenomicsAgreement to acquire3 midazolam nasal spray in epilepsy

Stronggrowth

Growth expansion

Breakthrough phase

2018 financial outlook confirmed

Achievements Q1 2018 vs priorities

*3 subject to the required antitrust filing and waiting period and customary closing conditions

2018 3M reportGrow core products 4

On track to deliver FY 2018 guidance

Numbers may not add due to roundingCER: constant exchange rate

€ million 3M 2018 3M 2017 Act CER

Revenue 1 070 1 124 -5% -1%

Immunology 310 317 -2% 8%

Cimzia® 310 317 -2% 8%

Neurology 529 537 -1% 8%

Vimpat® 242 239 1% 13%

Keppra® 189 210 -10% -3%

Briviact® 27 14 98% > 100%

Neupro® 71 74 -4% 1%

Combined net sales:€ 839 million (-2%; +8% CER)

Adjusted by allergy drugdivestiture: +0%; +4% CER

2018 3M reportAdvance and prepare launch of next wave 5

The trademark Evenity™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Evenity™ (romosozumab) is developed in partnership with Amgen globally.

Phase 3 program completedin bone loss disorders

Filing• EU (Jan. 2018)

• U.S. - Complete Response Letter (July 2017)

• Under regulatory review in Canada, Japan, Australia, Brazil and Switzerland

Evenity™(romosozumab)

Phase 2b program completed

Phase 3 • psoriasis start: Dec. 2017

(results end of 2019)

• psoriatic arthritis to start (H2 2018)

• ankylosing spondylitis to start (H2 2018)

bimekizumab

Phase 2a program completed

Phase 2b ongoing• highly drug-resistant

epilepsy start: Feb. 2018 (results H1 2020)

padsevonil

2018 3M report

Translating scientific hypotheses into clinical development6

1 APDS - Activated PI3K Delta Syndrome2 MG – myasthenia gravis

Evenity™ (romosozumab)osteoporosis

bimekizumab (IL17A/F)psoriasispsoriatic arthritisankylosing spondylitis

Phase 3 program results: end 2019

Phase 3 to start: H2 2018Phase 3 to start: H2 2018

dapirolizumab pegol (CD40L antibody)systemic lupus erythematosus Phase 2b results: Q4 2018 (Partner: Biogen)

padsevonil (PPSI)highly drug-resistant epilepsy Phase 2b results: H1 2020

seletalisib (PI3K δ inhibitor)Sjögren’s syndrome + APDS1 (Phase 1b) Phase 2a results: Q3 2018

rozanolixizumab (FcRn)immune thrombocytopenia + MG2 Phase 2a results: H2 2018

UCB4144 / VR942 - asthma (Partner: Vectura)

UCB6673 ; UCB7858 ; UCB0159

UCB3491 ; UCB0599 ; UCB0107

FilingPhase 3Phase 2Phase 1

Bone

Immunology

neurology

Evenity™ is the trade name of romosozumab which has been provisionally approved bythe U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).

2018 3M report

2018 2019 2020

R&D milestones

POS: partial onset seizrues, also known as focal seizures nr axSpA: non-radiographic axial spondyloarthritisSLE: Systemic Lupus ErythematosusPGTCS: Primary generalized tonic-clonic seizures

7

Cimzia®

rheumatoid arthritisfiling

(China)

dapirolizumab pegolSLE

Phase 2b results

Vimpat®

epilepsy PGTCS –adj. therapy

Phase 3 results

Cimzia®

psoriasis / psoriatic arthritis - Phase 3

results (Japan)

rozanolixizumabmyasthenia gravisPhase 2a results

padsevonilhigh drug resistant

epilepsyPhase 2b start

Cimzia®

psoriasisregulatory feedback

(U.S. / EU)

bimekizumab psoriasis

Phase 3 results

padsevonilhigh drug resistant

epilepsyPhase 2b results

seletalisibSjögren’s syndrome

Phase 2a results

Cimzia®

CRIB & CRADLE label extension

(EU)

romosozumabosteoporosis in

post-menopausal women

Filing (EU)

bimekizumab psoriatic athritisPhase 3 start

bimekizumab ankylosing spondylitis

Phase 3 start

Vimpat®

epilepsy POS –pediatric

Filing (Japan)

neurology

immunologybone

Cimzia®

CRIB & CRADLE label extension

(U.S.)

UCB0107Phase 1 start

Cimzia®

nr axSpAPhase 3 results

(U.S.)

rozanolixizumabITP

Phase 2a results

2018 3M reportContinued focus 8

internal & external opportunities

* subject to the required antitrust filing and waiting period and customary closing conditions

• Xyzal OTC (U.S.) - 2017

• 3 cardiovascular products - 2016

• nitrate business - 2016

• Shannon manufacturing site (Ireland) - 2016

• venlafaxine ER – 2016

• established brands (India) – 2015

•

- 2015

Divestitures Acquisitions & spin offs

Agreement to acquire* midazolam

nasal spray (USL261)in epilepsy

2018 3M report2018 financial outlook and midterm guidance 9

Maximize (new) growth drivers and strengthen sustainability

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge* ~188 million shares weighted average outstanding

2018 financial targets Guidance target 2021 and beyond

Revenue € 4.5 - 4.6 billion• Continued strong core product growth• One-time effects in 2017• Weak US$

rEBITDA / revenue ratio of 31% in 2021UCB investing into the pipeline complemented with inorganic growth opportunities

rEBITDA € 1.3 – 1.4 billion• R&D expense ratio of ~26% (+/-1% point)• Launch preparation

Updated peak sales guidanceBriviact® > € 600 million in 2026

Core EPS* € 4.30 – 4.70• Expected underlying tax ratio

in the "low twenties"

2018 3M reportUCB's patient value strategy 10

Our ambition is to be the patient preferred biotech leader,

creating patient value for specific populations through unique outcomes, the best experience

and improving as many of these lives as possible.

This will lead to sustainable growthfor UCB and its shareholders.

Value for patients

Mariana, living with epilepsy

Value for shareholders

2018 3M report

UCB's strategic growth pathTrue differentiation drives leadership and sustainability

Strong growth

Growth expansion

Breakthroughphase

11

Further factsand figures

12

2018 3M report 13Strong Cimzia® performance across all regions

1 Numbers may not add due to rounding 2 WOCBA/ women of child bearing ageCER: constant exchange rates 3 nr axSpA: non-radiographic axial spondyloarthritis

Label extension to include WOCBA2

(EU & U.S.) Rheumatoid arthritis: filing (China)• Psoriasis: potential approval (U.S. & EU)• Nr axSpA³: Phase 3 results (U.S.)• Psoriasis / psoriatic arthritis: Phase 3 results (Japan)

• Net sales to reach≥ € 1.5 billion

• Loss of exclusivity (U.S. & EU)

• Loss of exclusivity(Japan)

2018 2020 2024 2026

For patients living with• Rheumatoid arthritis• Psoriatic arthritis• Ankylosing spondylitis /

axial spondyloarthritis• Crohn’s disease

Net sales1


U.S. 180 200 -10% 4%

Europe 92 84 10% 11%

International markets 38 34 12% 24%

Total Cimzia® 310 317 -2% 8%

2018 3M reportCimzia® in-market performance 14

1 In-market growth is calculated for MAT period ; US : MAT Jan 2018 vs MAT Jan 2017; Europe & Japan : MAT Feb 2018 vs MAT Feb 20172 Market share is calculated for R3M period

6.3%

5.0%

5.5%

6.0%

6.5%

Jan-17 Apr-17 Jul-17 Oct-17 Jan-18

Cimzia® RheumatologyR3M Patient Share 2

-0.1%

3.9%

8.8%

-2%

0%

2%

4%

6%

8%

10%

Anti TNF Biologics Cimzia®

Cimzia® vs. Rheumatology Market Growth 1

U.S.

+8.9%

+0.5%

Source: U.S: IQVIA Source of Business Report January 2018

4.4%6.9%

16.3%

0%

5%

10%

15%

20%


Cimzia® vs. RA Market Growth 1

10.1%12.3%

7.3%

0%

5%

10%

15%

20%


Cimzia® vs. RheumatologyMarket Growth 1

Europe Japan

8.3%

7.0%

7.5%

8.0%

8.5%

9.0%

Feb-17 May-17 Aug-17 Nov-17 Feb-18

Cimzia® RheumatologyR3M Patient Share 2

-0.3%

Source: IMS MIDASIn-Market KPI’s are based on Exit Patients

+11.9%

4.5%

3.0%

3.5%

4.0%

4.5%

5.0%


Cimzia® RA R3M Patient Share 2

+0.5%

Source: IMS MIDAS; Cimzia® patients are considered 100% in RAIn-Market KPI’s are based on Exit Patients

-2.8%

2018 3M report 15Vimpat®

1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizuresCER: constant exchange rate 3 PGTCS: Primary Generalized Tonic-Clonic Seizures

• PGTCS3: Phase 3 results

• Net sales to reach≥ € 1.2 billion

• Patent expiry (U.S. & EU)

• Loss of exclusivity(Japan)

2019 2020 20242022

For patients living with epilepsy (partial onset seizures)• Adults, adolescents and

children from 4 years of age (EU & U.S.)

• Adults (Japan)• Adjunctive or monotherapy

Net sales1

2018

POS2: pediatric filing (Japan)


U.S. 177 186 -5% 10%

Europe 48 40 22% 22%


Total Vimpat® 242 239 1% 13%

2018 3M report

3.6%

2.8%

3.0%

3.2%

3.4%

3.6%

3.8%

Feb-17 Apr-17 Jun-17 Aug-17 Oct-17 Dec-17 Feb-18

Vimpat® – R3M TDx Share4.3%

3.5%

3.7%

3.9%

4.1%

4.3%

4.5%


Vimpat® – R3M TRx Share

0.9%

8.6%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TRx)

4.8%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TDx)

1.2%

18.0%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TDx)

Vimpat® in-market performance 16

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S.

+7.7%

+0.3%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

+16.8%

+0.6%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx

Numbers to be populated when sufficient data is

available

1.5%

0.0%0.2%0.4%0.6%0.8%1.0%1.2%1.4%1.6%


Vimpat® – R3M TDx Share

Source data JP: IMS MIDAS - In-market KPI’s are based on TDx

+1.2%

2018 3M report 17Keppra®

1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizuresCER: constant exchange rate 3 PGTCS: Primary Generalized Tonic-Clonic Seizures

• Patent expiry(Japan)

2020

For patients living with• epilepsy - POS2

• epilepsy - PGTCS3

• epilepsy - myoclonic seizures

Net sales1


U.S. 36 52 -31% -20%

Europe 56 61 -8% -7%


Total Keppra® 189 210 -10% -3%

• Patent expiry(U.S.)

2008

• Patent expiry(EU)

2010

2018 3M report

0.7%0.0%

0.5%

1.0%

1.5%

2.0%


Keppra® – R3M TRx Share12.5%

11.0%

11.5%

12.0%

12.5%

13.0%


Keppra® – R3M TDx Share

4.8%

27.6%

0%

10%

20%

30%

40%

AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

1.6%

2.0%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

0.7%

-13.0%-15.0%

-10.0%

-5.0%

0.0%

5.0%

AED Market Keppra®

Keppra® vs. AED Market Growth (TRx)

15.9%

12.0%

13.0%

14.0%

15.0%

16.0%

17.0%


Keppra® – R3M TDx Share

Keppra® in-market performance 18

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. For U.S., Keppra® includes Keppra® XR. For EU, Keppra® does not include UCB levetiracetam.

U.S.

-13.7%

-0.1%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-market KPI’s are based on TRx

+0.3%

+0.02%

Source data EU: IMS MIDAS - In-market KPI’s are based on TDx

+22.8%


+2.1%

2018 3M report 19Briviact®

1 Numbers may not add due to rounding CER: constant exchange rate

• Epilepsy POS2

Phase 3 results (Japan)

2020

For patients living with epilepsy (partial onset seizures)

• adjunctive therapy (EU & U.S.)• monotherapy (U.S.)

Net sales1


• Net sales to reach≥ € 600 million

2026


U.S. 21 11 93% > 100%

Europe 6 3 > 100% > 100%

International markets 0 0 > 100% > 100%

Total Briviact® 27 14 98% > 100%

• Pediatric: potential approval (U.S. & EU)

2018

2018 3M reportBriviact® in-market performance 20

A new therapeutic option in the AED market

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S. Europe

Source data U.S.: U.S. IMS NPAIn-Market KPIs are based on TRx

Source data EU: IMS MIDASIn-Market KPI’s are based on TDx

0.27%

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%


Briviact® – R3M TRx Share

0.67%

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%


Briviact® – R3M TDx Share

2018 3M report 21Neupro®

1 Numbers may not add due to rounding CER: constant exchange rate

• Net sales to reach≥ € 400 million

2020

For patients living with• Parkinson’s disease• restless legs syndrome

Net sales1

• Patent expiry (Japan)

2024


2021


U.S. 21 24 -10% 4%

Europe 43 39 10% 10%

International markets 7 11 -40% -34%

Total Neupro® 71 74 -4% 1%

2018 3M report

31.7%

25%

27%

29%

31%

33%

35%


Neupro® PD – R3M TDx Share

6.4%

6.0%

6.2%

6.4%

6.6%

6.8%

7.0%


Neupro® PD – R3M TRx Share

8.5%

14.3%

7.4%

0%2%4%6%8%

10%12%14%16%

PD Market PD KeyCompetitors

Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

15.9%

15.0%

15.2%

15.4%

15.6%

15.8%

16.0%


Neupro® PD – R3M TDx Share

-0.4% -3.3%

-4%-2%0%2%4%6%8%

10%


Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

-0.9% -0.9% -1.7%-4.0%

-2.0%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%


Neupro®

Neupro® PD vs. PD (KC) Market Growth (TRx)

Neupro® in-market performance 22

PD market: All molecules in ATC3= N4A. In the Europe and Japan, the TDx of all these molecules are factored for PD usage. In the U.S., only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usagePD Key Competitors (KC) market: The 8 DA’s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole. In the US, only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.

U.S.

-0.8%

-0.1%

Europe* Japan

Source data U.S.: U.S. IMS NPA - In-market KPI’s are based on TRx

-6.9%

+0.04%

Source data EU: IMS MIDAS - In-market KPI’s are based on TDx* Europe: factors have been updated & restated to 2017

+13.8%

+5.1%


2018 3M reportEvenity™ (romosozumab) 23

An innovative investigational bone-forming therapy

STRUCTURE, FRAME, BRIDGE and ARCH• Phase 3 studies completed

Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures

Dual effect on bone - increases bone formation and decreases bone resorption

Under regulatory review in the U.S., Canada, Japan, Australia, Braziland EU, Switzerland

• Complete Response Letter in the U.S. (July 2017)

Manorama, living with osteoporosis

*The trademark EVENITY™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).EVENITY™ (romosozumab) is developed in partnership with Amgen globally.

2018 3M report

Translating scientific hypotheses into clinical differentiation24

Dual blockade of IL-17F and IL-17A by bimekizumab

Dual blockade of IL-17F on top of IL-17A

will improve therapeutic efficacy versus targeting IL-17A alone

IL-17F

IL-17RAIL-17RC

IL-17A

Bimekizumab specifically and completely blocks IL-17F and IL-17A

IL-17F and IL-17A are twin cytokines

driving joint and skin inflammation

2018 3M report

• 250 patients living with chronic plaque psoriasis1

• 48 weeks

• placebo

• PASI90* response@ week 12

Psoriasis(NCT02905006)

Phase 2b results July 2017

Bimekizumab current development program 25

First monoclonal antibody neutralizing IL-17F on top of IL-17A

1 moderate to severe chonic plaque psoriasis* Defined as a patient who achieves 90% reduction from baseline in the PASI scoreSource: www.clinicaltrial.gov

Duration

Comparator

Endpoint

Results

• 303 patients living with ankylosing spondylitis

• 48 weeks

• placebo

• ASAS40 response @ week 12

Ankylosing spondylitis(NCT02963506)

Phase 2b results Dec 2017

• 206 patients living with active psoriatic arthritis

• 48 weeks

• placebo

• ACR50 response @ week 12

Psoriatic arthritis(NCT02969525)

Phase 2b results Dec 2017

All 3 studies in mixed population of anti-TNF-naïve and anti-TNF-incomplete responder patients

2018 3M reportNext: Phase 3 programs for clinical differentiation 26

Robust Phase 2b studies in 3 related indications

• All 3 studies met primary and secondary endpoints

• Rapid and profound clinical efficacy on relevant endpoints

• Both for joints and for skin

• Consistent across the three 12-week, mixed population, Phase 2b studies

• With a favorable safety profile

Data support initiation of Phase 3 program

for clinical differentiation in all 3 indications

2018 3M reportUCB FY 2017 financial highlights 27

Core product growth drive top and bottom line

CER: constant exchange rateOne-time other revenue of € 56 million for out-licensing the OTC-allergy drug Xyzal® (levoceterizine)

CER

+11%

+34%+33%

Actual

Revenue• Net sales up by 9% (+11% CER) to € 4.2 billion

driven by core products (€ 3.6 billion; +13%)

€ 4 530 million

Total operating expenses • Overall operating expense ratio improved to 48%• R&D expense +4%

€ 2 200 million

Recurring EBITDA • Higher gross profit • Improved operating expenses ratio

€ 1 375 million

Profit of the Group• € 753 million attributable to UCB shareholders (+45%)

€ 771 million

Core earnings per share Based on 188 million weighted average shares outstanding (2016: 188 million)

€ 4.82

+9%

+42%

+51% +52%

+2% +4%

+43%

2018 3M reportStrong net sales growth from core products 28

Generating € 3.6 billion (+13%)

CER = constant currency exchange rates* Excluding € 28 million from hedging ** adjusted for venlafaxine ER divestiture (net sales of €89m in 2016)

Cimzia® € 1.42 bn +9% (+11% CER)• Sustainable performance

Vimpat® € 0.98 bn +19% (+21% CER)• Strong, sustainable growth in all markets

Keppra® € 0.78 bn +8% (+11% CER)• Strong growth in international markets, especially in Japan

Briviact® € 87 million > +100%• Launched in EU countries and North America

Neupro® € 314 million +5% (+7% CER)• Sustainable growth in all geographies

Established brands -16% (-15% CER)• High value divestitures to increase focus and enhance strategic flexibility – adjusted** -3%

2017 FY net sales*€ 4 154 million

2018 3M report 2930% rEBITDA target for 2018 - already reached in 2017Top line growth, efficient resources allocation and tight cost control lead to improved ratios*

69% 69% 70% 71%74%

2013 2014 2015 2016 2017

60% 57% 55% 52%48%

2013 2014 2015 2016 2017

* vs. revenue

Gross margin / revenue Operating expense / revenue

17% 18%21%

24.9%

30.3%

2013 2014 2015 2016 2017

Recurring EBITDA / revenue

30% target for 2018

2018 3M reportSolid, sustainable top and bottom line growth 30

Strong foundation enabling future growth and investment in innovation

3.14 3.34 3.88

4.15 4.53

2013 2014 2015 2016 2017

€ bi

llion

0.54 0.61

0.82

1.03

1.38

2013 2014 2015 2016 2017

€ bi

llion

Recurring EBITDARevenue

2018 3M report2017 financial targets achieved 31

30.3 % rEBITDA margin – one year ahead of guidance

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge* Based on 188 million shares

Revenue € 4.4 - 4.5 billion € 4.53 billion (+9%)

rEBITDA € 1.25 – 1.35 billion€ 1.38 billion (+33%)

Core EPS* € 4.10 – 4.50€ 4.82 (+51%)

Net debt / rEBITDA = 1:1 by 20180.8 in 2016; 0.4 in 2017

rEBITDA / revenue ratio 30% in 201830.3% in 2017

'CVN' net sales ≥ € 3.1 billion by 2020€ 2.7 billion in 2017 (+12%)

Briviact® net sales ≥ € 450 million by 2026€ 87 million (+>100%) in 2017

2017 financial targets vs. 2017 achievements

Mid-term financial targets vs. 2017 achievements

2018 3M reportRecurring EBITDA 32

Solid growth - Improved operating expenses ratio

Restated after reclassification due to IFRS 15 EBIT: Earnings before interest and taxesCER: constant exchange rate EBITDA: Earning before interests, taxes, depreciation and amortization charges

2018 3M report2017 profit 33

CER: constant exchange rateEBIT: Earnings before interest and taxes

2018 3M reportCore earnings per share 34

Strong growth of core net profit

2018 3M report

Numbers may not add due to roundingCER: constant exchange rate

2017 key product net sales performance 35

2018 3M reportStrong Cash Flows 36

"Net debt/rEBITDA ratio of 1:1" achieved ahead of time in 2016

CAGR: composite annual growth rate* KU rEBITDA prior to KU divestment added back

Cash flow from continuing operations Net debt & recurring EBITDA ratio

€ m

illion

267

537

204

726

896

2013 2014 2015 2016 2017

3.06*

2.13*

KremersUrban

divestiture

nitrates, venlafaxine ER

divestiture

2018 3M reportOne UCB today: A global player 37

Presence in 38 countries complemented by a robust network of partners

Situation at 31 December 2017

7 478employees

globally

2018 3M report 38Stable shareholder base with free-float of 62%Weighted average shares outstanding in 2017: 188 million

“Free float” investors by region

Source: Notifications and UCB underlying ownership analysis, March 2018

2018 3M report 39

ן Antje Witte, Vice President Investor Relations• Phone: +32 2 559 9414• E-mail: [email protected]

ן Isabelle Ghellynck, Director Investor Relations• Phone: +32 2 559 9588• E-mail: [email protected]

ן Nathalie Deldime, Investor Relations Manager• Phone: +32 2 559 9291• E-mail: [email protected]

ן Check out our new IR App – stay tuned wherever you go

Your UCB Investor Relations team